IMMUNICUM AB (PUBL)

IMMUNICUM AB (PUBL)

Immunicum AB (publ) develops therapeutic cancer vaccines. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase I/II clinical trials to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise IMM-2 platform, which is in preclinical trials is transfected with an ad... enoviral vector to deliver tumor antigens directly to the immune priming cells; and IMM-3 platform that is in a preclinical phase study optimized CAR-T expansion protocol for improved anti-cancer activity. Immunicum AB (publ) has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase Ib/II study. The company is headquartered in Stockholm, Sweden.

Immunicum Ab (publ)_logo

Industry:
Company

Address:
Oestermalmstorg 5, Stockholm, Sweden Zipcode 114 42

Country:
Sweden

Phone:
46 8 732 8400

Market Cap:
920.57M
Total Assets:
728.66M
Total Cash:
167.64M

Founder: Alex Karlsson-Parra


Key Executives
Name Title Pay Year Born
Mr. Alex Karlsson-Parra Co-Founder & Chief Scientific Officer 176,000$ 1950(70 years old)
Mr. Erik Manting Ph.D. Chief Exec. Officer N/A 1971(49 years old)
Ms. Lotta Ferm Interim Chief Financial Officer N/A 1966(54 years old)
Mr. Sijme Zeilemaker Head of Investor Relations & Corp. Communication N/A 1987(33 years old)
Ms. Sharon Longhurst Head of CMC N/A 1969(51 years old)
Dr. Sven M. Rohmann Bus. Devel. Advisor N/A 1962(58 years old)
Dr. Jeroen Rovers Chief Medical Officer N/A 1971(49 years old)
Mr. Per-Olof Gunnesson Advisor Contracts N/A 1945(75 years old)



Financial & Stock
Exchange Stockholm. Currency in SEK. Market state POSTPOST
According to Immunicum Ab (publ)'s financial reports the company's revenue in 2020 were 0 an decrease(NAN%) over the years 2019 revenue that were of 0. In 2020 the company's total earnings were -89.25M while total earnings in 2019 were -134.02M(-33.58%).
Company's stock symbol is IMMU.ST. Lastest price : 5.54. Total volume :581.29k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.immunicum.se

  • Host name: dedi40.aname.net
  • IP address: 89.221.241.34
  • Location: Sweden
  • Latitude: 59.3247
  • Longitude: 18.056
  • Timezone: Europe/Stockholm

Loading ...
Loading ...


More informations about "Immunicum Ab (publ)" on Search Engine

Immunicum

Immunicum.se Immunicum Announces Investor Event and Conference Participation for April 07 Apr 2021; Notice of Annual General Meeting in Immunicum am (publ) 31 Mar 2021; Immunicum AB (publ) Announces Updated Executive Management Team After Business Combination 16 Mar 2021; See all

Immunicum

Immunicum.se Immunicum's Approach Activating the immune system against solid and blood-borne …

Immunicum

Immunicum.se Innovation in immuno-oncology. Immunicum is focused on demonstrating the therapeutic …

Immunicum

Immunicum.se Experience: Erik Manting worked for a number of years in the field of immunology before …

Immunicum

Immunicum.se Welcome to Immunicum's Investor Relations pages! Here you can find information which …

Immunicum

Immunicum.se Innovation in immuno-oncology. Analys. Immunicum omfattas av följande analytiker: …

Immunicum

Immunicum.se Title Type; Annual report 2019: pdf : Year-end report Jan-Dec 2019: pdf : Interim report …

Immunicum

Immunicum.se Immunicum AB and DCprime merged in December 2020, combining their …

Immunicum

Immunicum.se On Wednesday, November 18th Immunicum and DCprime combined forces to establish …

Immunicum

Immunicum.se Årsstämma i Immunicum AB (publ) Aktieägarna i Immunicum AB (publ) (“Bolaget”), org.nr …

Immunicum

Immunicum.se Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion …

Immunicum AB (publ) Publishes the Annual Report for 2020

Finance.yahoo.com Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a …

Immunicum AB (publ) Publishes the Annual Report for 2020

Uk.finance.yahoo.com 1 day ago · Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual Report for 2020 Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, [email protected]

Immunicum () : Publishes the Annual Report for 2020

Marketscreener.com 1 day ago · Press Release . 12 April 2021. Immunicum AB (publ) Publishes the Annual Report for 2020. Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com.. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, [email protected]

Immunicum AB (publ) Publishes the Annual Report for 2020

Bollyinside.com 1 day ago · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, [email protected]

Immunicum : Notice of Annual General Meeting in Immunicum

Marketscreener.com Mar 31, 2021 · Press Release . 31 March 2021. NOTICE OF ANNUAL GENERAL MEETING IN IMMUNICUM AB (PUBL) The shareholders of Immunicum AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Annual General Meeting (“AGM”) on Tuesday, 4 May 2021, at 10:30, at IVA:s Konferenscenter, at Grev Turegatan 16, Stockholm.Registration for the meeting will commence …

IMMU:Stockholm Stock Quote - Immunicum AB - Bloomberg …

Bloomberg.com Immunicum AB: Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment of Soft Tissue Sarcoma Jan 26, 2021 Immunicum AB: Report from the …

Notice of Annual General Meeting in Immunicum am (publ)

Itweekly.itbusinessnet.com Mar 31, 2021 · Press Release . 31 March 2021. NOTICE OF ANNUAL GENERAL MEETING IN IMMUNICUM AB (PUBL) The shareholders of Immunicum AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Annual General Meeting (“AGM”) on Tuesday, 4 May 2021, at 10:30, at IVA:s Konferenscenter, at Grev Turegatan 16, Stockholm.Registration for the meeting will commence …

Immunicum AB (publ) Announces Advancement to a Non

Investegate.co.uk Jun 15, 2020 · About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer.

Notice of Annual General Meeting in Immunicum am (publ)

Wallstreet-online.de Mar 31, 2021 · The shareholders of Immunicum AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Annual General Meeting (“AGM”) on Tuesday, 4 May 2021, at 10:30, at IVA:s ...

Press releases 2020 | Immunicum

Immunicum.se Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial 17 December 2020 Read more Immunicum AB (publ) Publishes Financial Calendar 2021 16 December 2020 Read more R Immunicum AB (publ) Provides Additional Information on the Proposed Transaction and Virtual Investor Event Summary

Immunicum AB (publ) Stock Forecast: down to 6.756 SEK

Walletinvestor.com Immunicum AB (publ) () Stock Market info Recommendations: Buy or sell Immunicum AB (publ) stock? Stockholm Stock Market & Finance report, prediction for the future: You'll find the Immunicum AB (publ) share forecasts, stock quote and buy / sell signals below.According to present data Immunicum AB (publ)'s IMMU shares and potentially its market environment have been in bearish cycle last 12 ...

Immunicum AB (publ) Announces Appointment of Jeroen Rovers

Finance.yahoo.com Immunicum AB (publ) Announces Appointment of Jeroen Rovers as Chief Medical Officer Immunicum AB (publ; IMMU.ST) announced today that Jeroen Rovers, M.D., …

Immunicum AB (publ) Receives FDA Orphan Drug Designation

Globenewswire.com Jan 26, 2021 · Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment of Soft Tissue Sarcoma (STS)

Immunicum AB: Immunicum AB (publ) Announces the

Bloomberg.com Aug 28, 2020 · Press Release 28 August 2020 Immunicum AB (publ) Announces the Appointment of Sven Rohmann as Chief Executive Officer Immunicum AB (publ: IMMU.ST) announced today that Sven Rohmann, M.D., Ph.D.,...

Immunicum AB (publ) Announces Transitions in Board of

Globenewswire.com Jan 21, 2021 · About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for …

Immunicum AB (publ) Announces Upcoming Virtual Investor

In.style.yahoo.com Immunicum AB (publ) Announces Upcoming Virtual Investor Event on December 9 th. Immunicum AB (publ; IMMU.ST) announced today that the Company will host a virtual Investor Event on Wednesday, December 9 th at 15:00 CET. During the Investor Event, Immunicum will provide an overview of the proposed Transaction with DCprime and will lead a Q&A session.

Immunicum AB (publ) Announces Updated Executive Management

Itbusinessnet.com Mar 16, 2021 · About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for …

Immunicum AB (publ) Announces Updated Executive Management

Ca.movies.yahoo.com Mar 16, 2021 · Press Release 16 March 2021 Immunicum AB (publ) Announces Updated Executive Management Team After Business Combination Immunicum AB (publ; IMMU.ST) announced today the establishment of an updated executive management team following the initial integration period of the business combination with DCprime that was completed in December 2020. In the new composition, …

Changes to the Nomination Committee for Immunicum AB (publ)

Internet.itbusinessnet.com Dec 29, 2020 · Press Release 29 December 2020 Changes to the Nomination Committee for Immunicum AB (publ) Immunicum AB (publ; IMMU.ST) announced today changes to the Nomination Committee as a result of the recently completed issue in kind in connection with the business combination with DCprime, whereby the ownership structure of Immunicum has changed. The composition of the...

Report from the Extraordinary General Meeting of Immunicum

Pharmaceuticaldaily.com Jan 22, 2021 · The information in this press release is information that Immunicum AB (publ) is obliged to disclose pursuant to Nasdaq Stockholm’s Rule Book for Issuers. The information was released for public disclosure through the contact person detailed below on 22 January 2021 at 14:00 CET. For more information, please contact:

Immunicum AB (publ) Publishes Prospectus for Admission to

View.news.eu.nasdaq.com Dec 18, 2020 · ABOUT IMMUNICUM AB (PUBL) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The Company’s lead product ilixadencel, consisting of pro ...

Immunicum AB (publ) Completes Business Combination with

News.yahoo.com Dec 21, 2020 · Press Release21 December 2020Immunicum AB (publ) Completes Business Combination with DCprimeImmunicum AB (publ; IMMU.ST) ("Immunicum" or the "Company") today completed the business combination with DCPrime BV, a Dutch clinical stage company developing cancer relapse vaccines aimed to reduce tumor recurrence, via the acquisition of all shares in …

Immunicum AB (publ) Receives FDA Orphan Drug Designation

Biopharmaglobal.com Jan 04, 2021 · Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)

Immunicum AB (publ) Receives Orphan Drug Designation from

Itbusinessnet.com Immunicum AB (publ; IMMU.ST) announced today that the European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the Company’s application for ...

Immunicum AB (publ) Interim Report January – September 2020

Nz.news.yahoo.com Press Release 5 November 2020Immunicum AB (publ) Interim Report January – September 2020July – September in Summary * Net sales for the period amounted to KSEK - (-). * Result for the period amounted to KSEK -22,244 (-29,643). * Earnings and diluted earnings per share totaled SEK -0.24 (-0.32). * Immunicum presented updated corporate and clinical development strategy. * Immunicum …

Immunicum AB (publ) Interim Report January – September 2020

Sg.news.yahoo.com About Immunicum AB (publ) Immunicum will become a cell therapy powerhouse in immuno-oncology by demonstrating the therapeutic value of its off-the-shelf immune primer, ilixadencel, in a broad range of solid tumor indications. Ilixadencel has achieved clinical proof-of-concept in a Phase II study, which showed its ability to provide a more durable and deeper anti-tumor response, resulting in ...

Immunicum AB (publ) Announces the Appointment of Sven

Investegate.co.uk Aug 28, 2020 · About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro ...

IMMUNICUM AB (PUBL): Receives FDA Orphan Drug Designation

Fdahealthnews.com IMMUNICUM AB (PUBL): Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)

Immunicum AB (publ) Announces Upcoming Virtual Investor

Uk.movies.yahoo.com Press Release 1 December 2020 Immunicum AB (publ) Announces Upcoming Virtual Investor Event on December 9th Immunicum AB (publ; IMMU.ST) announced today that the Company will host a virtual Investor Event on Wednesday, December 9th at 15:00 CET. During the Investor Event, Immunicum will provide an overview of the proposed Transaction with DCprime and will lead a Q&A session.

Immunicum AB (publ) Publishes Financial Calendar 2021 - 16

Wallstreet-online.de The information in this press release is information that Immunicum AB (publ) is obliged to disclose pursuant to Nasdaq Stockholm’s Rule Book for Issuers. The information was released for public ...

Immunicum AB (publ) Interim Report January – September 2020

Au.news.yahoo.com Immunicum AB (publ) Interim Report January – September 2020. July – September in Summary. Net sales for the period amounted to KSEK - (-). Result for the period amounted to KSEK -22,244 (-29,643).

Immunicum AB (publ) Announces Advancement to a Non

Unique.finance Immunicum AB (publ) Announces Advancement to a Non-Staggered Inclusion Phase in the Phase Ib/II ILIAD Combination Trial Immunicum AB (publ; IMMU.ST) announced today that the sixth patient has completed the safety period in the ongoing Phase Ib/II ILIAD combination trial with ilixadencel, the Company’s cell-based, off-the-shelf immune primer ...

Immunicum AB (publ) Announces Upcoming Investor

Uk.movies.yahoo.com Press Release 23 November 2020 Immunicum AB (publ) Announces Upcoming Investor Conferences in November and December Immunicum AB (publ; IMMU.ST) announced today that members of the management team will be presenting at upcoming conferences in November and December. Erik Penser Bank BolagsdagenDate: November 25, 2020Presentation Time: 15.20 CETLink: https://bit.ly/3pLfWHx …

Year-end report

Ml-eu.globenewswire.com Immunicum Group * On December 21, 2020, Immunicum AB acquired DCprime BV. The transaction resulted in the owners of the acquired company (DCprime) having deemed control of the acquiring company (Immunicum). The acquisition is therefore accounted for as a reverse acquisition. The consolidated financial

Changes to the Nomination Committee for Immunicum AB (publ)

Biospace.com Jan 30, 2019 · Immunicum AB (publ) (the "Company" or "Immunicum") announced the composition of the Nomination Committee on 19 October 2018. As a result of the recent new share issue, the ownership structure of the Company has changed and the Nomination Committee for the Annual General Meeting 2019 has changed in accordance with the rules of procedure adopted by the AGM.

Immunicum AB (publ) Announces Appointment of Jeroen Rovers

Bollyinside.com Mar 01, 2021 · Immunicum AB (publ; IMMU.ST) announced today that Jeroen Rovers, M.D., Ph.D., has been appointed to the position of Chief Medical Officer (CMO). The appointment is effective today. Dr. Rovers transitions from his role as Managing Director of DCprime and continues to serve on Immunicum’s management team.

BRIEF-Immunicum AB Presents Updated Data From Phase Ii

Reuters.com feb 6 (reuters) - immunicum ab: * reg-immunicum ab (publ) presents updated data from phase ii mereca trial of ilixadencel in kidney cancer at asco-sitc clinical immuno-oncology symposium

Immunicum AB (publ) Interim Report April - June 2018

Biospace.com Aug 17, 2018 · About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro ...

Immunicum AB (publ) Delårsrapport Q2 2018 – PM360

Pm360online.com Om Immunicum AB (publ) Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av lagringsbara allogena cellbaserade terapier. Vårt mål är att bekämpa cancer genom att aktivera och stärka patientens eget immunförsvar, och därmed förbättra överlevnad och livskvalitet. Företagets ledande produkt, ilixadencel ...